M
Marie Luisa Schmidt
Researcher at Humboldt University of Berlin
Publications - 22
Citations - 7674
Marie Luisa Schmidt is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 10, co-authored 15 publications receiving 4950 citations. Previous affiliations of Marie Luisa Schmidt include Friedrich Loeffler Institute & Charité.
Papers
More filters
Journal ArticleDOI
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
Victor M. Corman,Olfert Landt,Marco Kaiser,Richard Molenkamp,Adam Meijer,Daniel K.W. Chu,Tobias Bleicker,Sebastian Brünink,Julia Schneider,Marie Luisa Schmidt,Daphne G.J.C. Mulders,Bart L. Haagmans,Bas van der Veer,Sharon van den Brink,Lisa Wijsman,Gabriel Goderski,Jean Louis Romette,Joanna Ellis,Maria Zambon,Malik Peiris,Herman Goossens,Chantal B.E.M. Reusken,Marion Koopmans,Christian Drosten +23 more
TL;DR: A validated diagnostic workflow for 2019-nCoV is presented, its design relying on close genetic relatedness of 2019- nCoV with SARS coronavirus, making use of synthetic nucleic acid technology.
Journal ArticleDOI
Estimating infectiousness throughout SARS-CoV-2 infection course.
Terry Jones,Terry Jones,Terry Jones,Guido Biele,Guido Biele,Barbara Mühlemann,Barbara Mühlemann,Talitha Veith,Talitha Veith,Julia Schneider,Julia Schneider,Jörn Beheim-Schwarzbach,Tobias Bleicker,Julia Tesch,Marie Luisa Schmidt,Leif E. Sander,Florian Kurth,Florian Kurth,Peter Menzel,Rolf Schwarzer,Marta Zuchowski,Jörg Hofmann,Andi Krumbholz,Angela Stein,Anke Edelmann,Victor M. Corman,Victor M. Corman,Christian Drosten,Christian Drosten +28 more
TL;DR: In this article, the authors examined 25,381 German SARS-CoV-2 cases, including 6110 from test centers attended by pre-symptomatic, asymptomatic and mildly symptom-free (PAMS) subjects, 9519 who were hospitalised, and 1533 B.1.7 lineage infections.
Journal ArticleDOI
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Jakob Kreye,S. Momsen Reincke,Hans Christian Kornau,Hans Christian Kornau,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Elisa Sanchez-Sendin,Victor M. Corman,Hejun Liu,Meng Yuan,Nicholas C. Wu,Xueyong Zhu,Chang-Chun D Lee,Jakob Trimpert,Markus Höltje,Kristina Dietert,Laura Stöffler,Laura Stöffler,Niels von Wardenburg,Niels von Wardenburg,Scott van Hoof,Scott van Hoof,Scott van Hoof,Marie A Homeyer,Marie A Homeyer,Julius Hoffmann,Julius Hoffmann,Azza Abdelgawad,Achim D. Gruber,Luca D. Bertzbach,Daria Vladimirova,Lucie Y Li,Lucie Y Li,Paula Charlotte Barthel,Karl Skriner,Andreas C. Hocke,Stefan Hippenstiel,Martin Witzenrath,Norbert Suttorp,Florian Kurth,Florian Kurth,Christiana Franke,Matthias Endres,Dietmar Schmitz,Dietmar Schmitz,Lara Maria Jeworowski,Anja Richter,Marie Luisa Schmidt,Tatjana Schwarz,Marcel A. Müller,Christian Drosten,Daniel Wendisch,Leif E. Sander,Nikolaus Osterrieder,Nikolaus Osterrieder,Ian A. Wilson,Harald Prüss,Harald Prüss,Harald Prüss +58 more
TL;DR: Results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy and should be guided by immunization strategies.
Journal ArticleDOI
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Patricia Tscheak,Marie Luisa Schmidt,Marie Luisa Schmidt,Johanna Riege,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Florian Kurth,Victor M. Corman,Victor M. Corman,Leif E. Sander +30 more
TL;DR: In this article, an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19-BNT162b2 vaccination with a 10-12-week vaccine interval was performed.
Journal ArticleDOI
Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study.
Victor M. Corman,Verena Haage,Tobias Bleicker,Marie Luisa Schmidt,Barbara Mühlemann,Marta Zuchowski,Wendy K Jo,Patricia Tscheak,Elisabeth Möncke-Buchner,Marcel A. Müller,Andi Krumbholz,Jan Felix Drexler,Christian Drosten +12 more
TL;DR: The sensitivity range of most AgPOCTs overlaps with SARS-CoV-2 viral loads typically observed in the first week of symptoms, which marks the infectious period in most patients.